POEMs

Patient-Oriented Evidence That Matters

As-Needed Budesonide/Formoterol Similar to Maintenance Budesonide Plus SABA in Patients with Mild Asthma

 

Am Fam Physician. 2019 Nov 15;100(10):646-647.

Clinical Question

For patients with mild asthma, is as-needed use of an inhaled steroid/long-acting beta-agonist as effective as either as-needed albuterol alone or as-needed albuterol plus daily use of an inhaled steroid?

Bottom Line

In these patients with mild asthma (more than one-half used a short-acting beta-agonist [SABA] such as albuterol two or fewer times per week), as-needed use of a combined budesonide/formoterol (Symbicort) inhaler was as effective at preventing exacerbations as daily maintenance budesonide (Pulmicort) plus an as-needed SABA, and both were better than an as-needed SABA alone. The trial loses points for failing to mask outcome assessors and for having an imbalance in the number of previous severe exacerbations at baseline. (Level of Evidence = 1b–)

Synopsis

This study included patients with mild asthma who used a SABA alone at least twice in the previous three months, but no more than twice daily on average, and those who used a SABA alone and experienced a severe exacerbation in the past 12 months (7.3% of those enrolled). This raised the question of why a patient who had had a severe exacerbation (defined as requiring systemic corticosteroids or hospitalization) was being managed by a SABA alone. Patients hospitalized in the past 12 months were excluded. A total of 668 patients were randomized into one of three groups: (1) continued use of an as-needed SABA alone, (2) budesonide, 200 mcg twice daily, plus the SABA as needed, and (3) use of a combination inhaler containing 200 mcg of budesonide and 6 mcg of formoterol, one inhalation as needed to control symptoms. At baseline, there were some imbalances, with fewer women in the as-needed SABA group (50.7% vs. 55.5% to 57.3%), and more serious exacerbations in the past 12 months in the as-needed SABA group (20 vs. 17 for budesonide maintenance and only 12 for the budesonide/formoterol group). Analysis was by intention to treat, and only 13 patients were lost to follow-up during the one-year


Editor's Note: Dr. Ebell is Deputy Editor for Evidence-Based Medicine for AFP and cofounder and Editor-in-Chief of Essential Evidence Plus, published by Wiley-Blackwell.

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

 

 

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 1, 2019

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article